Eosinophilia and parasitic infestations in patients with chronic obstructive pulmonary disease

Narongkorn Saiphoklang & Chanya Chomchoey

Eosinophilia may guide response to inhaled corticosteroid treatment in patients with chronic obstructive pulmonary disease (COPD). This study aimed to determine prevalence of eosinophilia and parasitic infestations in these patients. We conducted a prospective cohort study between February 2019 and January 2020 and screened 107 stable COPD patients. A total of 77 subjects (84.4% men) were included. Age was 73.8 ± 8.9 years. Forced expiratory volume in 1 s was 66.5 ± 25.5%. Smoking history was 25.9 ± 18 pack-years. Comorbidities included cardiovascular disease (57.1%). Respiratory symptoms were assessed by modified Medical Research Council dyspnea score (1.6 ± 0.8), chronic obstructive pulmonary disease Assessment Test score (9.3 ± 4.9), and 6-min walking distance (317.2 ± 135.2 m). Patients with blood eosinophil count at least 100 cells/μL were 79.2% and at least 300 cells/μL were 33.8%. Intestinal parasites were not found. Significant positive correlations were found between high blood eosinophilia and some post-bronchodilator lung function parameters.

In conclusion, eosinophilic COPD was not uncommon. No intestinal parasite was found in this population. This study suggests that stool parasite exam might be omitted for routine practice.

Clinicaltrials.in.th Number: TCTR20191129002.

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation. It is commonly diagnosed in patient aged more than 40 years with chronic cough, dyspnea and/or history of exposure to risk factors for the disease. A major significant risk factor of COPD is cigarette smoking. Moreover, biomass fuel and dust particles are well known as risk factors besides smoking. According to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline, diagnosing COPD is supported by spirometry using post-bronchodilator FEV1/FVC ratio less than 0.7.

Assessment of blood eosinophil levels in COPD patients has an important role in COPD management. Previous studies showed the correlation between blood eosinophil level and incidence of exacerbation of the disease. High blood eosinophil count (BEC) is correlated with response to inhaled corticosteroid (ICS). There is a change of the current GOLD guideline for COPD management compared with the previous guideline. Clinical deterioration is assessed by modified Medical Research Council (mMRC) dyspnea scale ≥ 2 or COPD Assessment Test (CAT) score ≥ 10. Exacerbation history is considered as predictor of higher risk of COPD exacerbation. An exacerbation history with hospitalization in the last year or ≥ 2 moderate exacerbations per year with BEC ≥ 100 cell/µL should be prescribed inhaled corticosteroid plus long-acting beta-agonist (ICS/LABA). Moreover, COPD patients with an exacerbation and BEC ≥ 300 cell/µL are a significant prognosticator of better response to ICS. However, eosinophilia results from several etiologies such as parasitic infections, allergy, hematologic malignancies, and autoimmune diseases. The most common cause of high BEC in developing countries is parasitic infestation. In this study, we aimed to determine the prevalence of intestinal parasitic infestation in COPD patients with blood eosinophilia.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Thammasat University, 99/209 Paholyotin Road, Klong Luang, Pathum Thani 12120, Thailand. *email: m_narongkorn@hotmail.com
Methods

Study design. A prospective cohort study was conducted at Thammasat University Hospital in Thailand from February 2019 through January 2020. Stable COPD patients aged 40 years or older with smoking history more than 10 pack-years were recruited from COPD clinic. Exclusion criteria were history of COPD exacerbation in the past 3 months, other chronic respiratory diseases such as interstitial pulmonary fibrosis or bronchiectasis, inability to perform spirometry, inability to perform stool examination and complete blood count (CBC), inability to walk, diagnosis of asthma-COPD overlap (ACO), undergoing tracheostomy tube, use of mechanical ventilation, and treatment with systemic corticosteroid in the past 6 weeks. Patients' prescriptions were checked before every CBC measurement to ensure that all eosinophil counts were not affected by systemic corticosteroids.

Ethic approval was obtained from the Ethics Committee of Faculty of Medicine, Thammasat University (IRB No. MTU-EC-IM-1-265/61), in compliance with Declaration of Helsinki, The Belmont Report, CIOMS Guidelines and The International Practice (ICH-GCP). All methods were performed in accordance with these guidelines and regulations. All participants provided written informed consent.

Procedures. Patients demographic data, clinical characteristics, comorbidities, mMRC, CAT scores, vital signs, current medications, exacerbation history and vaccinations were recorded. CBC and stool samples were collected at the first date of the study and one week later. The stool test was done by simple smear method with direct saline stool microscopy for parasites. Stools were examined to detect common intestinal parasite species in each of two groups: helminths (echinostome, Gnathostoma spinigerum, hookworms, Opisthorchis viverrini, Strongyloides stercoralis, Taenia spp., Trichuris trichiura) and protozoa (Balantidium coli, Blastocystis hominis, Endolimax nana, Entamoeba coli, Entamoeba dispar, Entamoeba histolytica, Giardia intestinalis, Iodamoeba bütschlii, Sarcocystis hominis)⁹⁻¹⁳. Six-minute walk test (6MWT) and standard pre- and post-bronchodilator spirometry according to ATS/ERS guideline¹⁴ were performed in the first visit.

The patients were followed up 3 months later to evaluate respiratory symptoms and signs, perform spirometry and 6MWT for 6-min walking distance (6MWD) for assessment as well as CBC.

Outcomes. The primary outcome was the prevalence of parasitic infestation in COPD patients. Definition of parasitic infestation was presence of adult parasitic forms, larvae or ova in stool. The secondary outcome was the high BEC prevalence in COPD patients. We defined high blood eosinophils as 100 cells/µL or more.

Statistical analysis. Based on a previous study¹¹, prevalence of high BEC (> 150 cells/µL) in COPD was 20%. The sample size was calculated using 80% power, 5% type I error, and 10% precision margin. Thus, the sample size would be 62.

Statistical analyses were performed using SPSS version 20.0 software (IBM Corp., Armonk, NY, USA). Chi-squared test was used to compare categorical variables between two groups. ANOVA was used for comparison of 3 visits. Pearson correlation were used for correlation analysis between groups. A two-sided p-value < 0.05 was considered statistically significant.

Results

A total of 107 COPD patients were recruited. Of these, 77 patients were eligible for inclusion, however 30 patients were excluded (Fig. 1). At the end of the study, there were 71 patients who still participated. Mean age of the participants was 73.78 ± 8.91 years. Mostly, they were male. Mostly the participants were classified as COPD group B and were in grade 2 by spirometry classification. Cardiovascular disease was the most common of comorbidity. Moreover, common medications included long-acting muscarinic antagonists and LABA/ICS. Postbronchodilator FEV₁/FVC ratio was 58.64 ± 11.22. Generally, they did not have significant bronchodilator response by the evidence of FEV₁ and FVC change (Table 1).

No parasite was found by stool exam. All COPD patients had no symptoms of intestinal parasites including abdominal pain, diarrhea, vomiting, constipation, skin rashes or eczema, anemia, or unexplained weight loss. CBC data including BEC was not different in 3-month interval (Table 2). At baseline, BEC ≥ 100 cells/µL was found in 61 patients (79.2%), BEC ≥ 300 cells/µL was found in 26 patients (33.8%), and BEC ≥ 2% was found in 53 patients (68.8%). There was significant bronchodilator response by evidence of FEV₁ change in the high BEC group (Table 3).

Post-bronchodilator parameters were significantly higher than baseline data in 3-month interval (Table S1). In contrast, functional assessment was not different in 3-month interval (Table S2).

BEC was significantly correlated with post-bronchodilator FVC (r = 0.24, P = 0.041) and post-bronchodilator FEV₁ (r = 0.27, P = 0.023) (Table S3) but there was no correlation between BEC and mMRC, CAT scores or 6MWD (Table S4).

Discussion

Our study was the first prospective cohort study to determine prevalence of eosinophil and parasitic infestation. It has been shown that COPD patients in our setting were mostly in COPD grade 2 group B. ICS/LABA were used as the second most common treatment (50%).

A quarter of the subjects in our study had history of exacerbation in the previous year. Moreover, BEC at least 100 cells/µL were found commonly (79%). One-third of subjects (34%) had blood eosinophil levels of more than 300 cells/µL. From this evidence, it has been shown that high BEC was not uncommon in this Asian population. We knew that the most common cause of high blood eosinophil in Thailand was due to parasitic infestation and...
the most common parasite found was *Strongyloides stercoralis* in 33%\(^\text{11}\). Previous studies\(^\text{14,15}\) revealed that direct smear method for parasite exams had lower sensitivity than stool concentration techniques with formol ether or formalin-ethyl acetate concentration (12.5–61% vs 73.2–92%). However, our study was trying to improve the sensitivity by performing 2 consecutive stool exams (1-week interval). Our study found no parasites in these exams. This implied that health care and sanitation have improved in Thailand. Therefore, stool examination might be omitted in routine COPD patient care.

Previous studies of Vedel-Krogh et al.\(^\text{2}\) and Bafadhel et al.\(^\text{3}\) found that there was a relationship between high BEC and acute exacerbation of COPD (AECOPD) \(^\text{2,3}\). High BEC was also related with significant ICS response as shown in the study of Brightling et al.\(^\text{4}\).

The study of Kolsum et al.\(^\text{13}\) showed positive correlation between BEC and sputum eosinophil count. Balzano et al.\(^\text{16}\) found that high sputum eosinophil was correlated with low percent predicted of FEV\(_1\) and FEV\(_1\)/FVC ratio. However, our study did not perform sputum exam for eosinophils and did not find any correlation between BEC and AECOPD.

The study of Adir et al.\(^\text{17}\) showed that the number of patients who had percentage of BEC ≥ 2% was 71%. In our study, the result was almost the same (69%). There were several studies of COPD patients who had high BEC and percentage of eosinophils\(^\text{18-23}\). Prevalence of eosinophilia (≥ 2%) in our study was almost similar to the TRISTAN study\(^\text{21}\). Interestingly, our finding showed more patients with BEC > 300 cells/µL (33%) than in WISDOM study (20%)\(^\text{22}\).

In this study, we assumed that BEC was reliable because it did not fluctuate between 3 visits. Our study also strictly excluded patients who might have taken any medication that could have affected the BEC, especially systemic corticosteroids. There was a previous study of Oshagbemi et al.\(^\text{24}\) which supported this data especially in high BEC group (< 340 cells/µL) who had a tendency to have more BEC stability. A study of Southworth et al.\(^\text{25}\) found similar results. Repeated BEC measurements at 6 months or > 2 years remained in the same range using

---

**Figure 1.** Flow chart of patient recruitment to the study. COPD Chronic obstructive pulmonary disease, mMRC modified Medical Research Council, CAT COPD Assessment Test, CBC complete blood count, 6MWT Six-minute walk test.
| Characteristics                          | N = 77 |
|-----------------------------------------|--------|
| Age, years                              | 73.78 ± 8.91 |
| Male                                    | 65 (84.4) |
| BMI, kg/m²                               | 23.40 ± 4.40 |
| Smoking, pack-years                      | 23.9 ± 17.97 |
| Active smoking                           | 8 (10.4) |
| GOLD classification                      |        |
| A                                       | 28 (36.4) |
| B                                       | 31 (40.3) |
| C                                       | 5 (6.5) |
| D                                       | 13 (16.9) |
| Spirometry grading                       |        |
| 1                                       | 25 (32.5) |
| 2                                       | 31 (40.3) |
| 3                                       | 16 (20.8) |
| 4                                       | 5 (6.5) |
| Clinical history                         |        |
| AECOPD in last 1 year                    | 22 (28.6) |
| AECOPD with hospitalization in last 1 year | 18 (23.4) |
| Home oxygen supplementation              | 1 (1.3) |
| Oxygen saturation, %                     | 96.82 ± 1.52 |
| Medication                               |        |
| Inhaled short-acting bronchodilator      | 55 (71.4) |
| Inhaled long-acting muscarinic receptor antagonist | 39 (50.6) |
| Inhaled long-acting beta2 agonist        | 4 (5.2) |
| Inhaled long-acting muscarinic receptor antagonist plus long-acting beta2 agonist | 11 (14.3) |
| Inhaled corticosteroid plus long-acting beta2 agonist | 39 (50.6) |
| Oral bronchodilator                      | 5 (6.5) |
| Phosphodiesterase-4 inhibitor            | 3 (3.9) |
| Leukotriene receptor antagonist          | 7 (9.1) |
| Xanthine derivative                      | 18 (23.4) |
| Azithromycin                             | 4 (5.2) |
| Vaccination                              |        |
| Influenza vaccine within 1 year          | 55 (71.4) |
| Pneumococcal vaccine                     | 39 (50.6) |
| Comorbidity                              |        |
| Hypertension                             | 44 (57.1) |
| Benign prostatic hyperplasia             | 16 (20.8) |
| Allergic rhinitis                        | 14 (18.2) |
| Stroke                                  | 12 (15.6) |
| Coronary artery disease                  | 9 (11.7) |
| Chronic kidney disease                   | 7 (9.1) |
| Obstructive sleep apnea                  | 4 (5.2) |
| Lung tumor                               | 4 (5.2) |
| Congestive heart failure                 | 2 (2.6) |
| Spirometric data                         |        |
| Post-bronchodilator FVC, L              | 2.39 ± 0.79 |
| Post-bronchodilator FVC, % predicted    | 80.68 ± 19.12 |
| FVC change after bronchodilator, %      | 7.65 ± 12.82 |
| Post-bronchodilator FEV1, L             | 1.42 ± 0.58 |
| Post-bronchodilator FEV1, %predicted    | 66.49 ± 23.53 |
| FEV1 change after bronchodilator, %     | 9.08 ± 11.71 |
| Post-bronchodilator FEV1/FVC, %         | 58.64 ± 11.22 |
| Functional performance                   |        |
| mMRC                                    | 1.58 ± 0.81 |
| CAT score                               | 9.28 ± 4.89 |
| 6MWD                                    | 317.15 ± 135.25 |

Table 1. Demographic and baseline characteristics of COPD subjects. Data shown as mean ± SD or n(%). 
BMI: body mass index, kg kilogram, m meter, AECOPD acute exacerbation of chronic obstructive pulmonary disease, FVC forced vital capacity, l liter, FEV1 forced expiratory volume in 1 s, mMRC modified Medical Research Council, CAT COPD Assessment Test, 6MWD 6-minute walking distance.
Table 2. Comparison in complete blood count results between baseline, 1-week and 3-month follow-up. Data shown as mean ± SD, ANOVA was used for comparison of 3 visits. BEC, blood eosinophil count.

| Variables                  | Baseline    | 1-week follow-up | 3-month follow-up | P-value |
|----------------------------|-------------|------------------|-------------------|---------|
| Hemoglobin, g/dL           | 12.89 ± 1.75| 12.87 ± 1.81     | 12.96 ± 1.48      | 0.293   |
| White blood cell count, cells/µL | 7,344.00 ± 2,646.27 | 6,818.05 ± 2,157.15 | 7,610.91 ± 2,821.79 | 0.13    |
| Neutrophil, %              | 61.07 ± 11.04| 57.92 ± 9.24     | 61.72 ± 12.93     | 0.27    |
| Monocyte, %                | 8.97 ± 3.01  | 9.46 ± 4.19      | 8.66 ± 2.35       | 0.743   |
| Lymphocyte, %              | 24.99 ± 9.51 | 27.01 ± 8.87     | 24.66 ± 10.42     | 0.555   |
| Eosinophil, %              | 4.13 ± 3.99  | 4.92 ± 5.06      | 4.12 ± 4.39       | 0.072   |
| Basophil, %                | 0.67 ± 0.38  | 0.69 ± 0.39      | 0.68 ± 0.41       | 0.483   |
| Platelet, /µL              | 238,146.67 ± 67,108.16 | 240,175.68 ± 67,361.30 | 236,592.59 ± 83,024.10 | 0.816   |
| BEC, cells/µL             | 290.29 ± 290.20 | 297.85 ± 390.71 | 295.31 ± 386.35 | 0.192 |

Table 3. Characteristics of COPD patients with or without blood eosinophil count ≥ 300 cells/µL. Data shown as n (%). FVC forced vital capacity, L liter, FEV1 forced expiratory volume in 1 s, AECOPD acute exacerbation of chronic obstructive pulmonary disease.

| Characteristics                  | BEC<300 cells/µL (N = 49) | BEC≥300 cells/µL (N = 26) | P-value |
|-----------------------------------|---------------------------|---------------------------|---------|
| Male                              | 41 (83.7)                 | 22 (84.6)                 | 0.82    |
| Active smoking                    | 7 (14.3)                  | 1 (3.8)                   | 0.33    |
| AECOPD in last 1 year             | 15 (30.6)                 | 6 (23.1)                  | 0.63    |
| AE hospitalization group          | 14 (28.6)                 | 4 (15.4)                  | 0.32    |
| Home oxygen therapy               | 1 (2)                     | 0 (0)                     | 0.75    |
| Medication                        |                           |                           |         |
| Inhaled short-acting bronchodilator| 32 (65.3)                 | 21 (80.8)                 | 0.25    |
| Inhaled long-acting muscarinic receptor antagonist | 27 (55.1) | 11 (42.3) | 0.57 |
| Inhaled long acting beta2 agonist | 2 (4.1)                   | 2 (7.7)                   | 0.76    |
| Inhaled long acting muscarinic receptor antagonist plus long acting beta2 agonist | 9 (18.4) | 1 (3.8) | 0.8 |
| Inhaled corticosteroid plus long acting beta2 agonist | 24 (49) | 14 (53.8) | 0.92 |
| Oral bronchodilator               | 4 (8.2)                   | 1 (3.8)                   | 0.72    |
| Leukotriene receptor antagonist   | 4 (8.2)                   | 3 (11.5)                  | 0.80    |
| Xanthine derivative               | 13 (26.5)                 | 5 (19.2)                  | 0.57    |
| Azithromycin                      | 4 (8.2)                   | 0 (0)                     | 0.30    |
| Vaccination                       |                           |                           |         |
| Influenza vaccine within 1 year   | 36 (73.5)                 | 18 (69.2)                 | 0.74    |
| Pneumococcal vaccine              | 25 (51)                   | 14 (53.8)                 | 0.34    |
| Comorbidity                       |                           |                           |         |
| Hypertension                      | 29 (59.2)                 | 13 (50)                   | 0.35    |
| Coronary artery disease           | 6 (12.2)                  | 3 (11.5)                  | 0.87    |
| Congestive heart failure          | 2 (4.1)                   | 0 (0)                     | 0.56    |
| Chronic kidney disease            | 2 (4.1)                   | 5 (19.2)                  | 0.09    |
| Benign prostatic hyperplasia      | 12 (24.5)                 | 4 (15.4)                  | 0.50    |
| Obstructive sleep apnea           | 3 (6.1)                   | 1 (3.8)                   | 0.86    |
| Lung mass                         | 3 (6.1)                   | 1 (3.8)                   | 0.86    |
| Chronic thromboembolic pulmonary hypertension | 1 (2) | 0 (0) | 0.75 |
| Allergic rhinitis                 | 7 (14.3)                  | 7 (26.9)                  | 0.32    |
| Stroke                            | 8 (16.3)                  | 3 (11.5)                  | 0.34    |
| Spirometric data                  |                           |                           |         |
| FVC change after bronchodilator ≥ 200 mL | 12 (24.5) | 11 (42.3) | 0.52 |
| FEV1, change after bronchodilator ≥ 200 mL | 3 (6.1) | 8 (30.8) | 0.048 |
| FVC change after bronchodilator ≥ 12% | 10 (20.4) | 8 (30.8) | 0.71 |
| FEV1, change after bronchodilator ≥ 12% | 15 (30.6) | 11 (42.3) | 0.63 |
the 150 eosinophils per μL threshold. Therefore, using the 150 eosinophils per μL threshold indicated good long-term biomarker stability.

Review of Tashkin et al. showed diverse results between lung function parameter and BEC from various prior studies. Some studies showed that higher BEC was related to lower pulmonary function parameters but ECLIPSE study had opposite results. In the ECLIPSE study (n = 1,483), the patients with blood eosinophil persistently ≥2% (n = 554) had a higher mean percent predicted of FEV1 than that with blood eosinophil persistently < 2% (n = 201, 51% vs 48%; P = 0.009). The outcomes corresponded to our study.

Our study showed positive correlation between BEC and post-bronchodilator FVC as well as post-bronchodilator FEV1. Interestingly, FEV1 change of 200 ml was also significant in high BEC group. This might imply that high BEC patients had a tendency toward more bronchodilator reversibility.

In addition, we found no correlation between BEC and AECOPD, or between BEC and functional performances. After 3-month follow-up, functional performances had not improved significantly as lung function had, probably because higher lung function parameters did not reach the minimal clinically important difference (MCID) FEV1 was changed by 80 ml in our study. As a result, the enhancing functional performances were not obviously seen.

Clinical applications are proposed from our study. Firstly, CBC might need to be checked once because our study suggested the eosinophil level was not significantly different between 1-week interval and 3-month follow-up. Secondly, lung functions, particularly in bronchodilator reversibility, should be emphasized for patients with high eosinophil levels. Lastly, stool examination might not be necessarily be routinely tested in Thailand for COPD patient care.

Our study had a few limitations. Firstly, because of the small size of population, some results might not be obviously different between groups. Because this study was held in a single research center in Thailand, the result might not be applicable to other ethnicities or countries. Secondly, data on medication adjustment was not collected throughout the 3-month interval. Therefore, we could not assume that improvement of post-bronchodilator lung functions were solely as a result of high BEC, but this might be from some medications that were added to the treatment regimen. Lastly, due to limitation of direct stool exam, and because we did not do stool concentration methods for parasites, some parasites might not have been detected.

Conclusions
Eosinophilic COPD was not uncommon. In Thai COPD patients, parasitic infestation was not the main reason for high blood eosinophil. Thus, stool parasite exam might be omitted for routine COPD care.

Received: 25 April 2020; Accepted: 13 July 2020

Published online: 27 July 2020

References
1. Global Initiative for Chronic Obstructive Lung Disease. Global Initiative for Chronic Obstructive Lung Disease. GOLD 2019 Global Strategy for Diagnosis, Management and Prevention of COPD. accessed 31 October 2019. https://goldcopd.org.
2. Vedel-Krogh, S., Nielsen, S. E., Lange, P., Vestbo, J. & Nordestgaard, B. G. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 193, 965–974 (2016).
3. Bafadhel, M., Pavord, I. D. & Russell, R. E. K. Eosinophils in COPD: just another biomarker?. Lancet Respir. Med. 5, 747–759 (2017).
4. Brightling, C. E. et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 356, 1480–1485 (2000).
5. Celi, B. R. & Wedzicha, J. A. Update on clinical aspects of chronic obstructive pulmonary disease. N. Engl. J. Med. 381, 1257–1266 (2019).
6. Agusti, A. et al. Inhaled corticosteroids in COPD: friend or foe?. Eur. Respir. J. 52, 10 (2018).
7. Loscher, T. & Saathoff, E. Eosinophilia during intestinal infection. Best Pract. Res. Clin. Gastroenterol. 22, 511–536 (2008).
8. Assavapongpaiboon, B., Bunkasem, U., Sanprasert, V. & Nuchprayoon, S. A cross-sectional study on intestinal parasitic infections in children in suburban public primary schools, Saraburi, the central region of Thailand. Am. J. Trop. Med. Hyg. 98, 763–767 (2018).
9. Punsawad, C. et al. Prevalence of intestinal parasitic infection and associated risk factors among village health volunteers in rural communities of southern Thailand. BMC Public Health. 17, 564 (2017).
10. Boonjaraspinyo, S. et al. A cross-sectional study on intestinal parasitic infections in rural communities, northeast Thailand. Korean J. Parasitol. 51, 727–734 (2013).
11. Nuchprayoon, S., Siriyasatien, P., Kraivichian, K., Porkasorn, C. & Nuchprayoon, J. Prevalence of parasitic infections among Thai patients at the King Chulalongkorn Memorial Hospital, Bangkok, Thailand. J. Med. Assoc. Thai. 85(Suppl 1), S415–423 (2002).
12. Graham, B. L. et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am. J. Respir. Crit. Care Med. 200, e70–e88 (2019).
13. Kolsum, U. et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir. Res. 18, 88 (2017).
14. Laoprom, N. et al. Evaluation of a commercial stool concentrator kit: comparison to direct smear and formalin-ethyl alcohol concentration methods for diagnosis of parasitic infection with special reference to Opisthorchis viverrini sensu lato in Thailand. Southeast Asian J. Trop. Med. Public Health. 47, 890–900 (2016).
15. Haitu, T. & Abera, B. Performance evaluation of direct saline stool microscopy, Formol ether concentration and Kato Katz diagnostic methods for intestinal parasitosis in the absence of gold standard methods. Trop. Doct. 45, 178–182 (2015).
16. Baldano, G. et al. Eosinophilic inflammation in stable chronic obstructive pulmonary disease. Relationship with neutrophils and airway function. Am. J. Respir. Crit. Care Med. 160, 1486–1492 (1999).
17. Adir, Y., Hakrush, O., Shteinberg, M., Schene, S. & Agasti, S. Circulating eosinophil levels do not predict severe exacerbations in COPD: a retrospective study. ERI Open Res. 4, 3 (2018).
18. Wedzicha, J. A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 177, 19–26 (2008).
19. Vestbo, J. et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur. Respir. J. 31, 869–873 (2008).
20. Singh, D. et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur. Respir. J. 44, 1697–1700 (2014).
21. Pavord, I. D. et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax 71, 118–125 (2016).
22. Watz, H. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir. Med. 4, 390–398 (2016).
23. Hancox, R. J., Pavord, I. D. & Sears, M. R. Associations between blood eosinophils and decline in lung function among adults with and without asthma. Eur. Respir. J. 51, 4 (2018).
24. Oshagbemi, O. A. et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. Am. J. Respir. Crit. Care Med. 195, 1402–1404 (2017).
25. Southworth, T., Beech, G., Foden, P., Kolsum, U. & Singh, D. The reproducibility of COPD blood eosinophil counts. Eur. Respir. J. 52, 4 (2018).
26. Tashkin, D. P. & Wechsler, M. E. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 13, 335–349 (2018).
27. Barnes, N. C., Sharma, R., Lettis, S. & Calverley, P. M. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur. Respir. J. 47, 1374–1382 (2016).

Acknowledgements
The authors would like to thank Michael Jan Everts who is a lecturer at Faculty of Medicine in Thammasat University for proofreading this manuscript. The financial support was provided by Faculty of Medicine, Thammasat University, Thailand and Thoracic Society of Thailand under Royal Patronage.

Author contributions
N.S. and C.C. contributed to the design of this study. C.C. collected, analyzed and interpreted the data and drafted this manuscript. N.S. reviewed the final manuscript. All authors read, approved and agreed on the final manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-69541-7.

Correspondence and requests for materials should be addressed to N.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020